Unichem Laboratories Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Generics: 71.0% • Branded Generics: 15.5% • Active Pharmaceutical Ingredients (APIs): 10.3%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 24.1% CAGR over last 5 years
- Company is almost debt free
- Latest quarter profit grew 398.9% YoY, showing strong momentum
- Operating margins have improved to 3.6% from -4.8%
- Company comfortably covers its interest (18.7x coverage)
- Company generates healthy free cash flow
CONS
- Company has a low return on capital employed of 4.3%
- Company has a low return on equity of 3.1% over last 3 years
- A large part of profit comes from other income (30.0% of PBT)
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.36x)
- Working capital days have increased from 220 to 315 days
- Company has delivered a poor sales growth of 4.7% over past five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| UNICHEMLAB | 550.90 | 12.73 | 3878.65 | 0.00 | 41.47 | 496.08 | 632.62 | 20.13 | 10.68 | 11.06 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 347 | 334 | 362 | 399 | 390 | 437 | 448 | 461 | 384 | 357 | 315 | 356 | 366 | |
| 338 | 341 | 343 | 369 | 350 | 372 | 374 | 386 | 359 | 349 | 314 | 344 | 376 | |
| Operating Profit | 8 | -7 | 19 | 31 | 40 | 64 | 74 | 75 | 26 | 8 | 1 | 12 | -9 |
| OPM % | 2.40% | -2.19% | 5.33% | 7.66% | 10.31% | 14.76% | 16.57% | 16.26% | 6.70% | 2.16% | 0.44% | 3.51% | -2.55% |
| 6 | 8 | 78 | -119 | 9 | 7 | 19 | 10 | 4 | -12 | 291 | 10 | 17 | |
| Interest | 2 | 4 | 2 | 2 | 1 | 2 | 3 | 2 | 2 | 4 | 2 | 4 | 1 |
| Depreciation | 27 | 27 | 26 | 25 | 26 | 26 | 28 | 27 | 30 | 30 | 30 | 29 | 29 |
| Profit before Tax | -16 | -31 | 69 | -115 | 21 | 43 | 62 | 56 | -2 | -38 | 260 | -11 | 7 |
| Tax % | -0.00% | -0.00% | 0.00% | -0.00% | 0.00% | 0.00% | 24.13% | 8.58% | 1.07% | -5.55% | 16.82% | -43.70% | 25.07% |
| Net Profit | -16 | -31 | 69 | -115 | 21 | 43 | 47 | 51 | -2 | -40 | 216 | -15 | 6 |
| -2.23 | -4.38 | 9.85 | -16.33 | 3.05 | 6.16 | 6.66 | 7.28 | -0.26 | -5.67 | 30.69 | -2.19 | 0.79 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 576 | 666 | 968 | 904 | 1,124 | 943 | 1,072 | 1,442 | 1,736 | 1,412 | 1,394 | |
| 634 | 802 | 1,029 | 995 | 1,029 | 986 | 1,165 | 1,391 | 1,482 | 1,362 | 1,382 | |
| Operating Profit | -58 | -136 | -61 | -91 | 95 | -44 | -93 | 51 | 254 | 50 | 12 |
| OPM % | -10.07% | -20.45% | -6.28% | -10.02% | 8.49% | -4.62% | -8.66% | 3.53% | 14.63% | 3.57% | 0.88% |
| 7 | 63 | 102 | 99 | 47 | 42 | -71 | -27 | 45 | 290 | 305 | |
| Interest | 2 | 3 | 1 | 1 | 1 | 2 | 9 | 10 | 8 | 12 | 11 |
| Depreciation | 39 | 45 | 62 | 71 | 76 | 83 | 106 | 105 | 108 | 119 | 118 |
| Profit before Tax | -92 | -122 | -22 | -64 | 66 | -87 | -279 | -92 | 183 | 209 | 219 |
| Tax % | 18.11% | 0.12% | 132.63% | 11.75% | 17.61% | 36.10% | -7.39% | -0.00% | 10.79% | 24.10% | 23.94% |
| Net Profit | -76 | -121 | 7 | -56 | 54 | -55 | -300 | -92 | 163 | 159 | 166 |
| EPS | 11.41 | 281.70 | 1.25 | -8.00 | 7.68 | -7.87 | -42.57 | -13.09 | 23.15 | 22.58 | — |
| Dividend Payout % | -36.10% | -28.97% | 399.80% | -50.01% | 52.07% | -50.81% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 1%
- 5 Years:
- 5%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 5%
- 5 Years:
- 24%
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- 7%
- 5 Years:
- 14%
- 3 Years:
- 10%
- 1 Year:
- 10%
RETURN ON EQUITY
- 10 Years:
- -2%
- 5 Years:
- -1%
- 3 Years:
- 3%
- Last Year:
- 6%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| 1,111 | 2,747 | 2,714 | 2,628 | 2,676 | 2,647 | 2,358 | 2,277 | 2,441 | 2,607 | |
| 21 | 5 | 5 | 21 | 6 | 111 | 84 | 45 | 94 | 49 | |
| Trade Payables | 228 | 212 | 193 | 208 | 189 | 157 | 244 | 249 | 262 | 225 |
| 124 | 130 | 105 | 153 | 235 | 193 | 186 | 255 | 299 | 197 | |
| Total Liabilities | 1,503 | 3,108 | 3,030 | 3,025 | 3,119 | 3,122 | 2,886 | 2,842 | 3,109 | 3,092 |
| 464 | 551 | 785 | 825 | 846 | 963 | 1,236 | 1,165 | 1,275 | 1,189 | |
| Capital Work in Progress | 247 | 236 | 90 | 331 | 568 | 494 | 148 | 122 | 31 | 100 |
| 89 | 979 | 1,042 | 668 | 520 | 390 | 41 | 44 | 46 | 47 | |
| 254 | 208 | 274 | 316 | 386 | 461 | 480 | 501 | 584 | 592 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 558 | 748 | 583 | |
| Cash & Bank | 10 | 674 | 191 | 205 | 58 | 99 | 157 | 129 | 89 | 258 |
| 438 | 461 | 647 | 680 | 741 | 715 | 824 | 322 | 337 | 322 | |
| Total Assets | 1,503 | 3,108 | 3,030 | 3,025 | 3,119 | 3,122 | 2,886 | 2,842 | 3,109 | 3,092 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 168 | -68 | -244 | -44 | -32 | -162 | -117 | -42 | 72 | 53 | |
| Cash from Investing | -132 | 1,648 | -323 | -36 | -80 | 106 | 202 | 53 | -175 | 208 |
| Cash from Financing | -9 | -930 | -45 | -21 | -45 | 96 | -62 | -48 | 38 | -71 |
| -0 | 653 | -619 | -98 | -158 | 44 | 23 | -36 | -64 | 190 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | -8.31 | -17.26 | 1.00 | -8.00 | 7.68 | -7.87 | -42.57 | -13.09 | 23.15 | 22.58 |
| Book Value (₹) | 124.27 | 392.55 | 387.60 | 375.30 | 382.01 | 378.00 | 336.94 | 325.51 | 348.67 | 372.33 |
| Dividend per Share (₹) | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | -3.97 | -10.86 | 9.77 | 2.10 | 18.46 | 3.94 | -27.52 | 1.88 | 38.55 | 39.48 |
| PROFITABILITY | ||||||||||
| Operating Margin % | -8.81% | -11.00% | 4.21% | 0.95% | 12.71% | -0.16% | -4.76% | 3.53% | 14.63% | 3.57% |
| Net Margin % | -13.09% | -18.22% | 0.73% | -6.23% | 4.81% | -5.88% | -27.95% | -6.39% | 9.39% | 11.25% |
| ROE % | -7.01% | -6.24% | 0.26% | -2.10% | 2.03% | -2.07% | -11.91% | -3.95% | 6.87% | 6.26% |
| ROCE % | -8.33% | -6.08% | -0.76% | -2.32% | 2.50% | -3.08% | -10.21% | -3.38% | 7.72% | 8.43% |
| -5.25% | -5.27% | 0.23% | -1.86% | 1.76% | -1.78% | -9.98% | -3.22% | 5.48% | 5.13% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 178 | 145 | 106 | 132 | 111 | 143 | 145 | 130 | 137 | 172 |
| Inventory Days | 144 | 126 | 91 | 119 | 114 | 164 | 160 | 124 | 114 | 152 |
| Payable Days | 406 | 292 | 217 | 235 | 202 | 194 | 161 | 152 | 136 | 154 |
| -84 | -21 | -20 | 16 | 23 | 113 | 144 | 102 | 115 | 170 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.05x | 0.04x | 0.03x | 0.05x | 0.02x |
| Interest Coverage (x) | -45.17x | -37.38x | -33.97x | -48.78x | 51.47x | -40.82x | -28.75x | -7.85x | 24.97x | 18.75x |
| 2.28x | 7.48x | 6.82x | 4.32x | 3.51x | 4.42x | 3.33x | 2.97x | 3.01x | 4.87x | |
| GROWTH | ||||||||||
| Revenue Growth % | -52.80% | 15.62% | -21.41% | -6.54% | 24.27% | -16.11% | 13.73% | 34.48% | 20.35% | -18.63% |
| Operating Profit Growth % | -130.81% | -44.30% | -98.76% | -78.99% | 1568.75% | -101.04% | -3336.70% | 259.21% | 262.50% | -61.57% |
| Net Profit Growth % | -175.17% | -60.74% | -99.72% | -899.72% | 196.03% | -202.49% | -440.69% | 69.24% | 276.78% | -2.47% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 69.24% | 276.78% | -2.47% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 29.93x | 13.01x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 1.50x | 1.99x | 0.79x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 41.50x | 16.63x | 16.45x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-26 - Significant increase in volume has been observed in Unichem Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Unichem Laboratories Limited has submitted their response.
2026-08-25 - Significant increase in volume has been observed in Unichem Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
2026-08-12 - Unichem Laboratories Limited has submitted the Exchange a copy Srutinizers report of undefined held on August 11, 2026. Further, the company has informed the Exchange regarding voting results.
2026-08-12 - Unichem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication - Financial Results for the quarter ended June 30, 2026, published in the newspapers on August 12, 2026
2026-08-11 - Unichem Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026
2026-08-11 - Unichem Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-29 - Unichem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed
2026-07-14 - IPCA Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2026-07-10 - Significant movement in price has been observed in Unichem Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Unichem Laboratories Limited has submitted their response.
News
Recent coverage and analyst commentary for UNICHEMLAB
Loading news…
AI Stock Analyst
Unichem Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account